small molecule

TRYNGOLZA (AUTOINJECTOR)

OLEZARSEN SODIUM

Loss of exclusivityMay 2034latest FDA-listed patent expiry

CompanyIONIS PHARMACEUTICALS INC

Drug detail

Brand name	TRYNGOLZA (AUTOINJECTOR)
Active ingredient	OLEZARSEN SODIUM
Strength	EQ 50MG BASE/0.8ML (EQ 50MG BASE/0.8ML)
Dosage form	SOLUTION
Route	SUBCUTANEOUS
Modality	Small molecule
FDA approval	June 2026
Marketing status	RX

Listed patents

Patent	Expires	Type
12509684	May 2034	use U-4580
9181549	May 2034	substance
9127276	May 2034	substance
9163239	May 2034	substance
9157082	April 2032	use U-4580

Regulatory exclusivity

Code	Expires
NS	June 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from IONIS PHARMACEUTICALS INC